AIT-082 Phase 1B Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000180 |
Recruitment Status :
Completed
First Posted : November 1, 1999
Last Update Posted : December 11, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits.
This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Memory Disorders | Drug: AIT-082 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Masking: | Double |
Primary Purpose: | Treatment |
Actual Primary Completion Date : | June 2005 |
Actual Study Completion Date : | June 2005 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000180
United States, California | |
University of California, San Diego | |
San Diego, California, United States, 92093-0949 | |
United States, Indiana | |
Indiana University Alzheimer's Center | |
Indianapolis, Indiana, United States, 46202 | |
United States, Michigan | |
University of Michigan | |
Ann Arbor, Michigan, United States, 48109-0322 | |
United States, Missouri | |
Washington University | |
St. Louis, Missouri, United States, 63110 |
Principal Investigator: | Michael Grundman, M.D., M.P.H. | University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT00000180 |
Other Study ID Numbers: |
IA0008 3U01AG010483-08S2 ( U.S. NIH Grant/Contract ) |
First Posted: | November 1, 1999 Key Record Dates |
Last Update Posted: | December 11, 2009 |
Last Verified: | February 2005 |
Memory Mild cognitive impairment Nerve growth factors |
Memory Disorders Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases |